Endorepellin/Perlecan/Heparan Sulfate Proteoglycan Antibody (SPM255), Novus Biologicals™

Endorepellin/Perlecan/Heparan Sulfate Proteoglycan

Monoclonal

0.2mg/mL

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 1 - 2 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml

basement membrane-specific heparan sulfate proteoglycan core protein, endorepellin (domain V region), heparan sulfate proteoglycan 2, HSPG, perlecan, perlecan proteoglycan, PLCSchwartz-Jampel syndrome 1 (chondrodystrophic myotonia), PRCAN, SJA, SJS, SJS1

Rat

Protein A or G purified

RUO

3339

Human, Mouse, Porcine, Fish, Monkey, Primate

Purified

Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

SPM255

Unconjugated

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

HSPG2

Murine EHS laminin preparation

0.2 mg

Primary

This MAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment

Store at 4C.

IgG2a κ